
Halozyme Therapeutics, Inc.: stock overview
Price
$100.27
November 13, 2026Market cap $11.8B
What Ploutos Investor adds for Halozyme Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Halozyme Therapeutics had revenue of $1.8B over the last 12 months and net income of $485M, a net margin of 26.9%. Revenue grew by 39.2% a year on average over the last 5 years. At $100.27 the shares trade at a P/E of 24.4, against a median of 17.6 over the last 5 fiscal years. It has net debt of $2.2B. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $11.8B
- 118M shares
- P/E
- 24.4
- Today24.4Median17.6
- Revenue, 12 months
- $1.8B
- +39.2% a year over 5 years
- Net margin
- 26.9%
- 2025: 22.7%, above 88% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+29.8% a year over 2 years
Fiscal years in figures
HALO's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $5.9B
- $11.8B
- Enterprise value
- $14.0B
- P/E 3-year median: 17.6
- 24.4
- EV / EBIT
- 20.8
- EV / Revenue
- 7.8
- P/B 3-year median: 55.9
- –
- FCF yield 3-year median: 8.0%
- 7.5%
- Earnings yield 3-year median: 5.7%
- 4.1%
Profitability
- Gross margin
- 82.3%
- Operating margin
- 37.4%
- Net margin 3-year median: 34.0%
- 26.9%
- ROIC
- 20.7%
- ROIC, 5-year average
- 18.0%
- ROE
- 282.0%
Growth
- Revenue, yearly change
- +37.6%
- EPS, yearly change
- -25.4%
- FCF, yearly change
- +37.6%
- Revenue, average a year
- +39.2%
- EPS, average a year
- +23.0%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $1.1B
- Total debt
- $3.3B
- Of which operating leases
- $29M
- Net debt
- $2.2B
- Net debt / EBITDA
- 3.2x
- Interest cover
- 30.6x
- Current ratio
- 3.88
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- 2.89%
- Total returned
- 2.89%
- Shares, yearly change
- -4.2%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).
Operating margin
33.6%
Above 94% of the 285 companies in its industry, and 94% of all.
Net margin
22.7%
Above 88% of the 302 companies in its industry, and 85% of all.
ROE
649.2%
Above 99% of the 267 companies in its industry, and 100% of all.
ROA
12.6%
Above 85% of the 313 companies in its industry, and 91% of all.
Revenue growth
37.6%
Above 82% of the 292 companies in its industry, and 91% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- HALOZYME THERAPEUTICS, INC.
- CIK
- 1159036
- Exchange
- NASDAQ
- Industry (SIC)
- 2836 · Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 118M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with HALO
- JNJJohnson & Johnson+0,00%Compare with HALO
- ABBVAbbVie+0,00%Compare with HALO
- UNHUnitedHealth+0,00%Compare with HALO
- MRKMerck & Company+0,00%Compare with HALO
- AMGNAmgen+0,00%Compare with HALO
- TMOThermo Fisher Scientific+0,00%Compare with HALO
- ABTAbbott Laboratories+0,00%Compare with HALO
The full analysis
What do Halozyme Therapeutics's filings show?
These are Halozyme Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is HALO's market cap?
Halozyme Therapeutics, Inc.'s market cap is $11.8B, at a price of $100.27 on November 13, 2026 and 118M shares.
What is HALO's P/E?
HALO's P/E is 24.4, on earnings per share of $4.01 over the last 12 months. The median over the last 5 fiscal years was 17.6.
How much revenue does HALO have?
Halozyme Therapeutics had revenue of $1.8B over the last 12 months. Over the last 5 years it changed by +39.2% a year on average.
Does HALO pay a dividend?
No. Halozyme Therapeutics paid no regular dividend over the last 12 months.
Where do the figures come from?
From Halozyme Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.